Treatment of systolic hypertension: Spotlight on recent studies with angiotensin II antagonists

M. Volpe

Research output: Contribution to journalArticlepeer-review


Systolic blood pressure has a continuous, graded, strong, independent, and aetiologically significant relationship to mortality from coronary heart disease, stroke, and all cardiovascular diseases, as well as to all-cause mortality and life expectancy. Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility. All antagonists may therefore offer hitherto unrecognized benefits (independent of blood pressure) on age-related vascular damage and provide particular benefits in patients with systolic hypertension. Recent evidence has demonstrated that losartan offers cardiovascular outcomes benefits in isolated systolic hypertension (ISH) associated with an excellent tolerability profile. This, in patients with ISH, All antagonists more facilitate systolic BP control, providing cardiovascular protection and offering an excellent risk-benefit profile.

Original languageEnglish
Pages (from-to)93-102
Number of pages10
JournalJournal of Human Hypertension
Issue number2
Publication statusPublished - Feb 2005


  • Angiotensin II antagonists
  • Beta blockers
  • Cardiovascular disease
  • Diuretics
  • Isolated systolic hypertension
  • Losartan
  • Systolic hypertension

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Treatment of systolic hypertension: Spotlight on recent studies with angiotensin II antagonists'. Together they form a unique fingerprint.

Cite this